SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2002-01-0203. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0203v1 100/2/661    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Yavuz, A. S. Articles by Akin, C. Search for Related Content PubMed PubMed Citation Articles by Yavuz, A. S. Articles by Akin, C. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 July 2002, Vol. 100, No. 2, pp. 661-665 NEOPLASIA Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene A. Selim Yavuz, Peter E. Lipsky, Sule Yavuz, Dean D. Metcalfe, and Cem Akin From the Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD. Mast cells are derived from multipotential hematopoietic progenitors and are clonally increased in systemic mastocytosis, a disease associated with point mutations of codon 816 (most commonly Asp816Val) of c-kit. To study the lineage relationship and the extent of expansion of cells derived from the mutated clone, we examined the occurrence of the Asp816Val c-kit mutation in genomic DNA of individual sorted peripheral blood T cells, B cells, and monocytes in patients with indolent systemic mastocytosis. The mutation was detected in varying frequencies in the genomic DNA of individual B cells and monocytes and bone marrow mast cells in patients with extensive disease. In B cells, the immunoglobulin repertoire was polyclonal, indicating that the mutation occurred before VH/(D)/JH recombination. These results show that mastocytosis is a disorder of a pluripotential hematopoietic progenitor cell that gives rise to B cells and monocytes in addition to mast cells and that the affected clone shows variable expansion in these lineages in the peripheral blood of patients with systemic mastocytosis. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Pardanani, K.-H. Lim, T. L. Lasho, C. Finke, R. F. McClure, C.-Y. Li, and A. Tefferi Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies Blood, October 29, 2009; 114(18): 3769 - 3772. [Abstract] [Full Text] [PDF] N. S. Longo, P. L. Lugar, S. Yavuz, W. Zhang, P. H. L. Krijger, D. E. Russ, D. D. Jima, S. S. Dave, A. C. Grammer, and P. E. Lipsky Analysis of somatic hypermutation in X-linked hyper-IgM syndrome shows specific deficiencies in mutational targeting Blood, April 16, 2009; 113(16): 3706 - 3715. [Abstract] [Full Text] [PDF] N. S. Longo, G. J. Grundy, J. Lee, M. Gellert, and P. E. Lipsky An Activation-Induced Cytidine Deaminase-Independent Mechanism of Secondary VH Gene Rearrangement in Preimmune Human B Cells J. Immunol., December 1, 2008; 181(11): 7825 - 7834. [Abstract] [Full Text] [PDF] N. S. Longo, C. L. Satorius, A. Plebani, A. Durandy, and P. E. Lipsky Characterization of Ig Gene Somatic Hypermutation in the Absence of Activation-Induced Cytidine Deaminase J. Immunol., July 15, 2008; 181(2): 1299 - 1306. [Abstract] [Full Text] [PDF] K. Sotlar, A. Bache, F. Stellmacher, B. Bultmann, P. Valent, and H.-P. Horny Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis: A Distinct Subtype of Systemic Mastocytosis-Associated Clonal Hematological Nonmast Cell Lineage Disorder Carrying the Activating Point Mutations KITD816V and JAK2V617F J. Mol. Diagn., January 1, 2008; 10(1): 58 - 66. [Abstract] [Full Text] [PDF] K. J. Aichberger, M. Mayerhofer, K. V. Gleixner, M.-T. Krauth, A. Gruze, W. F. Pickl, V. Wacheck, E. Selzer, L. Mullauer, H. Agis, et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412 Blood, April 1, 2007; 109(7): 3031 - 3041. [Abstract] [Full Text] [PDF] D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF] A. Tan, D. Westerman, G. A. McArthur, K. Lynch, P. Waring, and A. Dobrovic Sensitive Detection of KIT D816V in Patients with Mastocytosis Clin. Chem., December 1, 2006; 52(12): 2250 - 2257. [Abstract] [Full Text] [PDF] A. C. Garcia-Montero, M. Jara-Acevedo, C. Teodosio, M. L. Sanchez, R. Nunez, A. Prados, I. Aldanondo, L. Sanchez, M. Dominguez, L. M. Botana, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients Blood, October 1, 2006; 108(7): 2366 - 2372. [Abstract] [Full Text] [PDF] C. Akin Molecular Diagnosis of Mast Cell Disorders: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 412 - 419. [Abstract] [Full Text] [PDF] A. I. Schafer Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood, June 1, 2006; 107(11): 4214 - 4222. [Abstract] [Full Text] [PDF] K. V. Gleixner, M. Mayerhofer, K. J. Aichberger, S. Derdak, K. Sonneck, A. Bohm, A. Gruze, P. Samorapoompichit, P. W. Manley, D. Fabbro, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects Blood, January 15, 2006; 107(2): 752 - 759. [Abstract] [Full Text] [PDF] J. P. Zappulla, P. Dubreuil, S. Desbois, S. Letard, N. B. Hamouda, M. Daeron, G. Delsol, M. Arock, and R. S. Liblau Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation J. Exp. Med., December 19, 2005; 202(12): 1635 - 1641. [Abstract] [Full Text] [PDF] M. L. Taylor, D. Sehgal, M. Raffeld, H. Obiakor, C. Akin, R. G. Mage, and D. D. Metcalfe Demonstration That Mast Cells, T Cells, and B Cells Bearing the Activating Kit Mutation D816V Occur in Clusters within the Marrow of Patients with Mastocytosis J. Mol. Diagn., November 1, 2004; 6(4): 335 - 342. [Abstract] [Full Text] [PDF] C. Akin, G. Fumo, A. S. Yavuz, P. E. Lipsky, L. Neckers, and D. D. Metcalfe A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib Blood, April 15, 2004; 103(8): 3222 - 3225. [Abstract] [Full Text] [PDF] S. O'Brien, A. Tefferi, and P. Valent Chronic Myelogenous Leukemia and Myeloproliferative Disease Hematology, January 1, 2004; 2004(1): 146 - 162. [Abstract] [Full Text] [PDF] A. D. Klion, P. Noel, C. Akin, M. A. Law, D. G. Gilliland, J. Cools, D. D. Metcalfe, and T. B. Nutman Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness Blood, June 15, 2003; 101(12): 4660 - 4666. [Abstract] [Full Text] [PDF] G. Sommer, V. Agosti, I. Ehlers, F. Rossi, S. Corbacioglu, J. Farkas, M. Moore, K. Manova, C. R. Antonescu, and P. Besmer Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase PNAS, May 27, 2003; 100(11): 6706 - 6711. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020